Author:
Yang Zhong-min,Liao Xue-mei,Chen Yi,Shen Yan-yan,Yang Xin-ying,Su Yi,Sun Yi-ming,Gao Ying-lei,Ding Jian,Zhang Ao,He Jin-xue,Miao Ze-hong
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference22 articles.
1. Wang YQ, Wang PY, Wang YT, Yang GF, Zhang A, Miao ZH . An update on poly(adp-ribose)polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy. J Med Chem 2016; 59: 9575–98.
2. Clovis Oncology, Inc. FDA accepts Clovis Oncology'S new drug application for rucaparib for priority review for the treatment of advanced mutant BRCA ovarian cancer. http://phx.corporate-ir.net/phoenix.zhtml?c=247187&p=irol-newsArticle_Print&ID=2196955 .
3. TESARO, Inc. TESARO's niraparib significantly improved progression-free survival for patients with ovarian cancer in both cohorts of the phase 3 NOVA trial. http://ir.tesarobio.com/releasedetail.cfm?ReleaseID=977524 .
4. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010; 17: 688–95.
5. Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 2013; 3: 68–81.
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献